Introduction {#S0001}
============

Chimeric Antigen Receptor T(CAR-T) cell therapy is an immunotherapy approach used in treating cancer which has seen rapid development over the decades.[@CIT0001] In CAR-T cell therapy, the patient's T cells are equipped with the ability to detect and destroy cancer cells by combining the specificity of a monoclonal antibody with the cytotoxic and memory capabilities of the T cells.[@CIT0002] The production of CAR-T cell therapy first involves the collection of T cells, a type of white blood cell from a patient (autologous), or a donor's (allogeneic) blood. The collected T cells are engineered in the laboratory to produce chimeric antigen receptors on their surface. The CAR-T cells are infused into the bloodstream of the patient aiming at the identification and killing of the malignant cells that have the targeted antigen on their surface and multiply within the patient's body.

CD19 is an IgSF surface glycoprotein of 95kDa expressed during the earliest stages of B cell development until it is lost during the differentiation of plasma cell terminal, therefore, making it a potential target against B-cell malignancies.[@CIT0003] Maude et al (2014) reported that about 90% of patients with relapsed or refractory acute lymphoblastic leukaemia (ALL) who received CD19 CAR-T cell therapy achieved complete remission up to 2 years.[@CIT0004] Less than half of the patients enrolled in Cruz et al (2013) studies attained complete and partial remission and 8 out of 11 patients diagnosed with lymphoma had up to 23 months' remission.[@CIT0005] Wang et al (2014) showed that a patient achieved a complete remission up to 9 weeks after administering CAR-T cells.[@CIT0006] The variance in these studies may be due to several factors such as the source of T cells being either allogeneic or autologous, infused CAR-T cell doses, days of cell culture, chemotherapy regime for lymphodepletion and the production design making it difficult for comparative studies. Per our knowledge, previous studies focused on the safety and efficacy of CD20 and CD19 CAR-T cells with limited number involved.[@CIT0007],[@CIT0008] Zhang et al evaluated the efficacy of both autologous and allogeneic CD19 CAR-T cells in 131 patients.[@CIT0009] Zhou et al reported the safety and efficacy of CD20 and CD19 CAR-T cells in 185 patients.[@CIT0010] Anwer et al included allogeneic T cells, though most CAR-T cell treatment utilises autologous T cells[@CIT0011] and Holzinger et al studies were a narrative review, instead, of a systematic one.[@CIT0012] Most studies conducted so far combined both allogeneic and autologous CD19 and CD20 in their studies.

Given these impediments of past publications, along with the quick advancement of the CAR- T field, we conducted a meta-analysis study to investigate the efficacy and survival outcome of autologous CD19 CAR-T cell therapy by involving 320 patients from 14 studies and figuring out factors affecting CAR-T therapy efficacy, survival outcome, and distinguish the group of patients (Paediatric or Adult) with the better outcome.

Methods and materials {#S0002}
=====================

Literature searching and screening {#S0002-S2001}
----------------------------------

With the search words "CD19ʹ', "autologous", "hematological malignancies" and "CAR-T", we conducted a search from Pubmed, Google Scholar and Baidu Xueshu databases for the related scientific studies from May 15 to September 23, 2018. All relevant articles related to the study were incorporated.

Exclusion and inclusion criteria {#S0002-S2002}
--------------------------------

The inclusion criteria included: (1) only reported clinical trials; (2) autologous CD19 CAR-T cell; (3) relapsed or refractory B-cell hematological malignancies; (4) studies conducted in humans and (5) literature published in English. The criteria for exclusion included: (1) allogeneic CD 19; (2) autologous or allogeneic CD 20; (3) studies not conducted in humans; and (4) studies not published in English.

Data extraction and quality assessment {#S0002-S2003}
--------------------------------------

The data we extracted from each study included the principal author, year of publishing, number of patients involved, the method of gene transfer, category of patient, type of disease, type of chemotherapy regime for lymphodepletion, costimulatory domains, time of T cell culture, infused CAR-T cell doses, response outcome and toxicity. Patients whose death was unrelated to the malignancies and lost follow-up were not included for analysis. The percentage of patients who attained partial and complete remission was used to calculate the rate of response.

For detailed analysis, lymphodepletion was assessed by "No" and "Yes"; category of patient was assessed by "Paediatric" and "Adult"; T cell culture time was assessed by "More than 14 days" and "Less than 14 days"; Total infused T cell was analyzed by "cells more than 10[@CIT0007]" and "cells less than 10[@CIT0007]".

Statistical analysis {#S0002-S2004}
--------------------

Of the studies examined, the total estimation of response rate and toxicity was evaluated, using the R software (version 3.5.1) and the estimation was done on the basis of a random-effects model, in which the inter-study variability was evaluated using the Der-Simonian Laird estimator. The outcomes of the overall response rate and toxicity for all the included studies were presented using forest plots. The proportion of response rate from each study was presented with exact binomial 95% confidence intervals (CIs). If heterogeneity was not present (I[@CIT0002] \<50%), a fixed effect model was applied for analysis; otherwise, a random effect model was adopted. Funnel plots and Egger's rank correlation test were used to assess potential publication bias. Possible publication bias is said to occur when there is a deficiency in the base of the funnel with asymmetry. We performed subgroup analysis to discover possible factors connected with efficacy and response rate. Data was transferred from an Excel spreadsheet to SPSS version 21.0 for survival analysis.

Results {#S0003}
=======

A total of 320 patients with 98 being paediatric and 222 being adult from 14 clinical trials were involved in our study analysis ([Figure 1](#F0001){ref-type="fig"}). 77 were lymphoma patients, 190 ALL patients and 53 chronic lymphocytic leukaemia (CLL) patients. Figure 1Flow diagram of the selection process.

Patient characteristics and treatment procedure {#S0003-S2001}
-----------------------------------------------

Patient characteristics were included in [Tables 1](#T0001){ref-type="table"} and [2](#T0002){ref-type="table"}.[@CIT0004],[@CIT0013]--[@CIT0023] All patients received autologous CD19 CAR-T cells. Three patients were given CAR-T of the third-generation with the costimulatory domains CD137 and CD28. Lentivirus and gammaretrovirus were used to introduce the constructed CAR into the T cells. One hundred and ninety-one (191) patients received chemotherapy regimen for lymphodepletion. The number of CAR-T cell infused ranged between 2×10^5^--11×10^8^. Table 1Patients CharacteristicsName of authorNo. of patientsCategory of patientsType of diseaseMethod of gene transferAg recognition moietiesCostimulatory domainsOrigin of T cellsTurtle 2015[@CIT0013]34AdultB NHL=28LentivirusCD194-1BBAutologousCLL=6Porter 2015[@CIT0014]14AdultCLLLentivirusCD194-1BBAutologousPorter 2014[@CIT0015]26AdultCLLLentivirusCD194-1BBAutologousSchuster 2015[@CIT0016]24AdultB-NHLLentivirusCD194-1BBAutologousPorter 2014[@CIT0015]12AdultALLLentivirusCD194-1BBAutologousGrupp 2015[@CIT0017]53PediatricALLLentivirusCD194-1BBAutologousLee 2015[@CIT0018]20PediatricALLRetrovirusCD19CD28AutologousKochendefer 2012[@CIT0019]8AdultB NHLRetrovirusCD19CD28AutologousCLLKochenderfer 2015[@CIT0020]15AdultB-NHLRetrovirusCD19CD28AutologousBrentjens 2013[@CIT0021]46AdultALLRetrovirusCD19CD28AutologousTurtle 2015[@CIT0013]29AdultALLLentivirusCD194-1BBAutologousSavoldo 2011[@CIT0022]6AdultNHLRetrovirusCD19CD28AutologousMaude 2014[@CIT0004]30PediatricALLRetrovirusCD194-1BBAutologousKalos 2011[@CIT0023]3AdultALLRetrovirusCD19CD28Autologous Table 2Response rate subgroup analysesName of authorLymphodepletion ChemotherapyCulture time of T cellsGeneration of CARTNumber of infused T cellsTreatment ResponseTurtle 2015[@CIT0013]Cyclophosphamide 60 mg/kg ×1± etoposide OR Cyclophosphamide 60 mg/kg ×1± Fludarabine 25 mg/m^2^×3 days12 days2^nd^2×10^5^, 2×10^6^ and 2×10^7^/kgCR=13PR=7Porter 2015[@CIT0014]NA10--12 days2^nd^0.14--11×10^8^/kgCR=4PR=4Porter 2014[@CIT0015]NA10--12 days2^nd^5×10^7^ vs 5×10^8^CR=5PR=4Schuster 2015[@CIT0016]NA10 days2^nd^3.08--8.87×10[@CIT0006]/kgCR=15Porter 2014[@CIT0015]NA10 days2^nd^6.5--8.45×10[@CIT0006]/kgCR=8Grupp 2015[@CIT0017]NA13 days2^nd^1.07--17.36×10[@CIT0006]/kgCR=50Lee 2015[@CIT0018]Cyclophosphamide 900 mg/kg ×1+ Fludarabine 25 mg/m^2^×3 days11 days2^nd^1×10^6^ vs 3×10^6^/kgCR=14Kochendefer 2012[@CIT0019]Cyclophosphamide 60 mg/kg ×2+ Fludarabine 25 mg/m^2^×5 days24 days2^nd^0.3--3.0×10^7^/kgCR=1PR=5Kochenderfer 2015[@CIT0020]Cyclophosphamide 60 mg/kg ×1--2+ Fludarabine 25 mg/m^2^×5 days11 days2^nd^1--5×10^6^/kgCR=8Brentjens 2013[@CIT0021]Cyclophosphamide 60 mg/kg ×1+ Fludarabine 25 mg/m^2^×3 days8 days2^nd^1×10^6^ vs 3×10^6^/kgCR=37Turtle 2015[@CIT0013]Cyclophosphamide 60 mg/kg ×1+ Fludarabine 25 mg/m^2^×3 days14 days2^nd^2×10^5^, 2×10^6^ and 2×10^7^/kgCR=24Savoldo 2011[@CIT0022]NA6--18 days2^nd^1--5×10^6^/kgPD=4SD=2Maude 2014[@CIT0004]Cyclophosphamide 60 mg/kg ×1+ Fludarabine 25 mg/m^2^×3 days OR Cyclophosphamide 60 mg/kg ×1± etoposide12 days2^nd^0.3--9.58×10^8^/kgCR=27NR=3Kalos 2011[@CIT0023]Cyclophosphamide, Pentostain, Bendamustine, Rituximab10 days3^rd^0.14--11×10^8^/kgCR=2PR=1

Response rate and toxicity {#S0003-S2002}
--------------------------

The evaluated response rate and the 95% confidence interval (CI) from the various studies are shown in [Figure 2](#F0002){ref-type="fig"}. The total assessment of response rate from the 14 studies included in our analysis was 71.88% (95% CI: 61.34--80.46%) with substantial heterogeneity observed (I^2^ =65%, X^2^ =37.42, *p*\<0.01). Subgroup analyses of response rate were evaluated, and the outcomes have been presented in ([Table 3](#T0003){ref-type="table"}). We discovered that lymphodepletion patients arm group had a greater response rate (77%, 95%CI: 67--83%; *p*-value =0.001) in comparison to the other patients who did not (66%, 95%CI: 41--83%). The overall estimate of CRS toxicity in our analysis was 60.15% (95% CI: 42.87--75.22%) with a considerable heterogeneity detected (I^2^= 83%, X^2^ =77.85, *p*\<0.01). [Figure 3](#F0003){ref-type="fig"} shows the overall estimated CRS toxicity and the 95% CI from the various studies. Table 3Response rate subgroup analysesPrognostic factorNo. of studyResponse rate (95%CI)*P*-valueLymphodepletion\
Yes\
No\
8\
6\
0.77 (0.67--0.83)\
0.66 (0.41--0.83)\
0.001T cell culture time\
More than 14 days\
Less than 14 days\
4\
10\
0.67 (0.56--0.76)\
0.65 (0.53--0.76)\
0.203Total CAR-T cells infused\
More than 10[@CIT0007]\
Less than 10[@CIT0007]\
6\
8\
0.80 (0.52--0.99)\
0.77 (0.67--0.84)\
0.193Category of patient\
Adult\
Paediatric\
11\
3\
0.72 (0.56--0.84)\
0.66 (0.52--0.78)\
0.054 Figure 2Forest plot for response rate and 95% CI based on individual study and the entire study.Figure 3Forest plot for CRS toxicity and 95% CI based on individual study and the entire study.

Patient survival outcome {#S0003-S2003}
------------------------

The 1-year and 6-month progression-free survival (PFS) for 163 patients were 38% and 82% respectively. The mean interval of PFS was 10 months (95% CI: 5.9--13.9), and the median interval of PFS was 7 months (95% CI: 0.16--13.8), shown in ([Figure 4](#F0004){ref-type="fig"}). The overall survival (OS) for 6 months was 65%, and the median interval of OS was 7.8 months (95% CI: 0.60--15.0). ([Figure 5](#F0005){ref-type="fig"}) Figure 4Progression-free survival (PFS) curve.Figure 5Overall survival (OS) curve.

Heterogeneity sources {#S0003-S2004}
---------------------

The proof of substantial bias in publication (*p*=0.0167) was detected by the Egger's regression asymmetry test. [Figure 6](#F0006){ref-type="fig"} shows the funnel plot of the response rate for publication bias. The funnel plot is used as a visualising aid in identifying systematic heterogeneity or bias. A symmetrical inverted funnel shape arises from a set of ' well - behaved ' data in which bias in publications did not occur. An asymmetric funnel shows an association between study accuracy and treatment effect estimate. Figure 6Funnel plot of response rate for publication bias.

Discussion {#S0004}
==========

CAR-T cell immunotherapy has advanced rapidly and emerges as an effective way of treating patients with refractory or relapse B cell malignancies. The greatest challenge in CAR-T cell immunotherapy is how to increase and improve efficiency while reducing the toxicity related to the treatment. In our meta-analysis, the overall pooled toxicity was 60.15% (95%CI: 42.87--75.22%). CRS and on target/off-tumour effect are the significant toxicities associated with CART cell therapy. CRS is an inflammatory response syndrome caused by cytokine secretion in light of CAR-T cells activation. Three out of the 14 studies included in our meta-analysis reported grade 3 and 4 CRS incidence and severity, indicating a well-tolerated infusion of CAR-T cells in the other studies. The high toxicity in the three studies can be attributed to an increase in inflammatory cytokine. Corticosteroids and tocilizumab can be used to manage these adverse effects such as hypotension, fever, and rigours associated with CRS which mostly emerge within the first 24 hrs after CAR-T cells infusion. Two (2) studies again reported B cell aplasia. B cell aplasia is an on-target off tumour effect due to response in normal cells with the CAR-targeted antigen.[@CIT0009] To manage on target off tumour side effects like B cell aplasia, inducible caspase 9, a suicide gene has been integrated into CAR construction to regulate CAR-T cell persistence.[@CIT0023]

The total pooled response rate was 71.88%(95%CI: 61.34--80.46%) higher than previous studies from Hou et al and Zhang et al. According to reports, first, second, and third generations chimeric antigen receptors (CARs) were present. Reported studies suggested that CARs of the second generation with an activation domain facilitated quick amplification, activation and the continuance of T cells in comparison to CARs of the first generation.[@CIT0024] More research is needed to verify the efficacy of the second generation. The third generation was not evaluated because of limited data. It remains to be explained whether chimeric antigen receptors (CARs) are better in the third generation than CARs in the second generation. The costimulatory CAR-T domains are normally used with CD137 or CD28. Which costimulatory domain has improved efficiency remains a mystery. No subgroup analysis was done between these two types of the costimulatory domain in our studies; however, some studies have shown that CD137 increased T cell expansion and persistence compared to CD28[@CIT0025],[@CIT0026] because CD137 lacks maturity and CD137 with CARs present may escalate acute toxicity and the continuance of the infused T cells. There was no test to juxtapose the effectiveness of the costimulatory signal, so both clinical and basic research are needed.

No common consensus has been reached among various researchers whether a patient should receive lymphodepletion or not. Lymphodepletion is the depletion of the receipt lymphocytes before infusing CAR-T cells. Lymphodepleting chemotherapy may improve CAR-T cell responses by getting rid of regulatory T cells, removing other immune cells which could challenge for homeostatic cytokines, and improving antigen - presenting cell activation. Before the T cell infusion, Lymphodepletion was administrated in the vast majority of the preliminaries. Our studies demonstrated that a higher and better response rate for patients who received lymphodepletion administering before T cell infusion than those who did not receive it. Furthermore, better prognosis in terms of survival analysis was also achieved in the lymphodepletion group of patients with a significant *p*-value.

These results indicate a correlation between lymphodepletion and better clinical outcomes; however, we did not conduct any analysis to know which type of B cell malignancies had a better response when lymphodepletion chemotherapy is administered.

Cytokines have been recognised to be useful in the expansion of T cells. The previous report showed that IL-2 promoted the expansion of T cells which affected the efficacy.[@CIT0027]--[@CIT0030] We observed a similar result in our studies correlating with previous studies, but more studies are needed to clarify whether administering IL-2 to T cells or patient or not has better efficacy.

A viral vector or electroporation is the means of transducing constructed CAR to T cells. Viral transduction technique has greater transduction efficiency in comparison to the electroporation technique but also increases the chances of viral insertional oncogenesis. Viral transduction was employed by all the studies included in our analysis. More trials are needed to evaluate gene transfer efficiency between gamma retrovirus transduction and lentivirus transduction. The strength of our research lies in its sample size and also it is the first systematic review and meta-analysis which focuses on only autologous CD19 CAR-T cell therapy. Nevertheless, there are some limitations to our study. Firstly, the articles included were not entirely prospective studies. Secondly, no subgroup analysis was conducted between different ethnicities and ages.

Conclusion {#S0005}
==========

In conclusion, the results of our studies demonstrated a more significant clinical response rate of autologous CD19 CAR-T cells in hematological malignancies. We again demonstrated that lymphodepletion regimen is associated with a better clinical response rate. We hope that knowledge from retrospective studies combined with advanced technology would improve the clinical efficacy of autologous CD19 CAR-T cells in treating refractory or relapse B cell malignancies.
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